ARVNArvinas, Inc.
Price
-19%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality shaky, a flag to check, growth fading, the market against it.
Charts
As reported to the SEC, without any scoring.
Arvinas, Inc. (ARVN) reported revenue of $250M in Q2 2026 (quarter ended Jun 30, 2026), up 1015% from the same quarter a year earlier. That came with net income of $169M (68% of revenue). For the full year FY2025, revenue was $263M (−0.3% year on year) and net income −$81M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jun 22, 2026On June 22, 2026, Arvinas, Inc., a Delaware corporation (the “Company”), and Noah Berkowitz, M.D., Ph.D., the Company’s chief medical officer, agreed that Dr. Berkowitz would depart from his employment with the Company, effective July 3, 2026 (the “Departure”)Director or officer change · Form 8-K
- Jun 16, 2026As previously announced, on May 11, 2026, Arvinas, Inc., a Delaware corporation (“Arvinas”), and Arvinas’ direct subsidiaries, Arvinas Operations, Inc. (“Operations”) and Arvinas Estrogen Receptor, Inc. (“Arvinas ER,” together with Arvinas and Operations, the “Company”), together with Pfizer Inc. (“Pfizer”), entered …Other event · Form 8-K
- Jun 2, 2026Following a strategic review of its pipeline, the Company has made the decision to re-prioritize its portfolio.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry